ANDA 206908, held by Gland. Levofloxacin.
As of Nov 16, 2026, ANDA 206908 (Levofloxacin In Dextrose 5% In Plastic Container), held by Gland, was first approved by FDA on Dec 30, 2020, with 1 approved supplement and 0 published complete response letters.
Levofloxacin Injection is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin Injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1, 12.4 ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 30, 2020 | Original application | Approved | None posted |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 250MG/50ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Rx |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 500MG/100ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Rx |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 750MG/150ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 30, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters